Cancer Chemotherapy and Pharmacology

, Volume 27, Issue 5, pp 379–384 | Cite as

Kinetics of melphalan leakage during hyperthermic isolation perfusion in melanoma of the limb

  • H. F. Rauschecker
  • H. Foth
  • H. C. Michaelis
  • F. Horst
  • W. Gatzemeier
  • C. Willenbrock
  • E. Voth
  • G. F. Kahl
Original Articles Melphalan, Kinetics, Leakage, Melanoma, Limb, Perfusion


The kinetics of melphalan leakage into the peripheral blood were studied in 21 patients undergoing hyperthermic isolation perfusion of the upper or lower limb as an adjuvant treatment in high-risk melanoma; in 5 patients cisplatin was added. The melphalan concentrations in the peripheral blood rose predominantly during the first 20 min of perfusion and levelled out to an apparent steady state of about 0.28 μg/ml in upper extremity perfusions, and 0.34 (without cisplatin) and 0.37 μg/ml (with cisplatin) in lower extremity perfusions. Erythrocytes labelled with technetium Tc 99m, which were added concomitantly with melphalan to the perfusion medium, appeared in the systemic circulation of the patients at an almost constant rate of 0.32% (lower and upper limb perfusions without cisplatin and 0.37% (with cisplatin) of total tracer/min. This perfusate flow rate indicated by labelled erythrocytes completely explained the leakage of melphalan from the perfusion circuit into the peripheral blood. Peak concentrations of melphalan in the peripheral blood were observed immediately after reconstitution of normal hemodynamic conditions once isolation perfusion had been teminated. This fraction of melphalan might originate from tissue-binding sites, but also from vascular compartments; therefore, a thorough washing-out procedure might minimize this effect.


Melanoma Melphalan Technetium Perfusion Medium Perfusate Flow 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ardiet C, Tranchand B, Biron P, Rebattu P, Philip T (1986) Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis (report in 26 cases). Cancer Chemother Pharmacol 16: 300Google Scholar
  2. 2.
    Barcroft H (1963) Circulation in skeletal muscle. In: Handbook of physiology, vol II Circulation. Americal Physiology Society, Washington, p 1353Google Scholar
  3. 3.
    Bauer R, Bauer U, Sauer E, Langhammer H, Pabst HW (1981) In vivo/in vitro-Markierung von Erythrozyten mit99mTc und ihre klinische Anwendung. Nucl Compact 12: 18–25Google Scholar
  4. 4.
    Benckhuisen C, Varossieau FJ, Hart AAM, Wieberdink J, Noordhoek J (1986) Pharmacokinetics of melphalan in isolated perfusion of the limbs. J Pharmacol Exp Ther 237: 583Google Scholar
  5. 5.
    Benet LZ, Sheiner LB (1985) Design and optimization of dosage regimens; pharmacokinetic data. In: Goodman S, Gilman A (eds), The pharmacological basis of therapeutics, 7th edn. Macmillan, New York, p 1663Google Scholar
  6. 6.
    Bosanquet AGA, Gilby ED (1982) Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur J Cancer Clin Oncol 18: 355Google Scholar
  7. 7.
    Ehrsson H, Ekborg S, Osterborg A, Mellstedt H, Lindfors A (1989) Oral melphalan pharmacokinetics — relation to dose in patients with multiple myeloma. Med Oncol Tumor Pharmacother 6: 151Google Scholar
  8. 8.
    Gera S, Musch E, Osterheld HKO, Loos U (1989) Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma. Cancer Chemother Pharmacol 23: 76Google Scholar
  9. 9.
    Ghussen F, Nagel K, Groth W, Müller JM, Stützer H (1984) A prospective randomized study of regional extremity perfusions in patients with malignant melanoma. An Surg 200: 764Google Scholar
  10. 10.
    Gouyette A, Hartmann O, Pico JL (1986) Pharmacokinetics of high-dose melphalan in children and adults. Cancer Chemother Pharmacol 16: 184Google Scholar
  11. 11.
    Hafström L, Hugander A, Jönsson PE, Westling H, Ehrsson H (1984) Blood leakage and melphalan leakage from the perfusion circuit during regional hyperthermic perfusion for malignant melanoma. Cancer Treat Rep 68: 867Google Scholar
  12. 12.
    Krementz ET, Carter RD, Sutherland CM, Muchmore JH (1987) Chemotherapy by regional perfusion for limb melanoma. Am Surg 53: 133Google Scholar
  13. 13.
    Lejeune FJ, Ghanem EG (1987) A simple and accurate new method for cytostatics dosimetry in isolation perfusion of the limbs based on exchangeable blood volume determination. Cancer Res 47: 639Google Scholar
  14. 14.
    Martijn H, Schrafford Koops H, Milton GW, Nap M, Oosterhuis JW, Shaw HM, Oldhoff J (1986) Comparison of two methods of treating primary malignant melanomas Clark IV and V, thickness 1.5 mm and greater, localized on the extremities. Wide surgical excision with and without adjuvant regional perfusion. Cancer 57: 1923Google Scholar
  15. 15.
    Milnor WR (1974) In: Mountcastle VB (ed) Medical physiology 13. Mosby, St. LouisGoogle Scholar
  16. 16.
    Minor DR, Allen RE, Alberts D, Peng YM, Tardelli G, Hutchinson J (1985) A clinical and pharmacokinetic study on isolated limb perfusion with heat and melphalan for melanoma. Cancer 55: 2638Google Scholar
  17. 17.
    Rege VB, Leone AL, Soderberg CH, Coleman GV, Robidoux HJ, Fijman R, Brown J (1983) Hyperthermic adjuvant perfusion chemotherapy for stage I malignant melanoma of the extremity with literature review. Cancer 52: 2033Google Scholar
  18. 18.
    Taha IA, Ahmad RA, Gray H, Roberts CI, Rogers HJ (1982) Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma. Cancer Chemother Pharmacol 9: 57Google Scholar
  19. 19.
    Woodhouse KW, Henderson DB (1981) High pressure liquid chromatographic method for the determination of melphalan in plasma. Proceedings, Meeting of the British Pharmacological Society, December 16–18, p 605Google Scholar
  20. 20.
    Woodhouse KW, Hamilton P, Lennard A, Rawlins MD (1983) The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen. Eur J Clin Pharmacol 24: 283Google Scholar
  21. 21.
    Zucchetti M, D'Incalci M, Willems Y, Cavalli F, Sessa C (1988) Lack of effect of cisplatin on i. v.l-PAM plasma pharmacokinetics in ovarian cancer patients. Cancer Chemother Pharmacol 22: 87Google Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • H. F. Rauschecker
    • 1
  • H. Foth
    • 2
  • H. C. Michaelis
    • 2
  • F. Horst
    • 1
  • W. Gatzemeier
    • 1
  • C. Willenbrock
    • 1
  • E. Voth
    • 3
  • G. F. Kahl
    • 2
  1. 1.Department of SurgeryUniversity of GöttingenGöttingenGermany
  2. 2.Department of Pharmacology and ToxicologyUniversity of GöttingenGöttingenGermany
  3. 3.Department of Nuclear MedicineUniversity of GöttingenGöttingenGermany

Personalised recommendations